- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03536767
Open-Label Study of AG10 in Patients With Cardiomyopathy
An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
Study Overview
Detailed Description
An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
The primary objective of this study is to evaluate the long-term safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who have completed the study AG10-201.
This study will be an Open-Label Extension and Safety Monitoring Study of up to 55 male and/or female patients with symptomatic ATTR-CM aged 18 through 90 years, who have completed the Phase II Study AG10-201. Enrollment into the study will be followed by visits at Day 14, Day 45, 3 Months and every 3 months thereafter until Month 54. After the Month 54 Visit, study visits will be every 6 months. There will be one follow-up visit approximately 30 days after last dose.
If all doses are well tolerated, the duration of each patient's participation in the study will continue based on periodic recommendations of the AG10 Data Monitoring Committee (DMC) and/or registration of the product for the treatment of symptomatic ATTR-CM.
The secondary objectives of this study are to characterize the pharmacokinetics (PK) of AG10 administered orally twice daily in patients with symptomatic ATTR-CM, and to describe the long-term pharmacodynamic (PD) properties of AG10 as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the PK-PD relationship of AG10 in adult patients with symptomatic ATTR-CM.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29424
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Completed participation in study AG10-201.
- Willing and able to comply with the study medication regimen and all study requirements.
- The ability to understand and provide informed consent, which must be obtained prior to initiation of study participation.
- Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use effective method(s) of contraception.
Exclusion Criteria:
- Hemodynamic instability that would pose too great a risk to the subject.
- Abnormalities in clinical laboratory tests that would pose too great a risk to the subject.
- Any clinically significant ongoing medical condition or any laboratory abnormality or condition that could adversely affect the safety of the patient.
- Known hypersensitivity to study drug (AG10), its metabolites, or formulation excipients.
- Likely to undergo heart transplantation or placement of a mechanical circulatory device within the next year.
- Receiving current treatment with diflunisal, tafamidis, green tea, doxycycline, TUDCA/Ursodiol, patisiran, inotersen or any other investigational ATTR agent within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to dosing with study drug.
- Females who are pregnant or breastfeeding. Lactating females must agree to discontinue nursing before the study drug is administered.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Open-Label
|
AG10 800mg twice daily, oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of long-term safety and tolerability: Incidence of each treatment-emergent adverse events
Time Frame: up to 60 Months or study completion by recommendation from safety monitoring committee
|
Incidence of each treatment-emergent adverse events
|
up to 60 Months or study completion by recommendation from safety monitoring committee
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AG10 Pharmacokinetics AUC
Time Frame: up to 60 Months or study completion by recommendation from safety monitoring committee
|
Area under the plasma concentration-time curve (AUC)
|
up to 60 Months or study completion by recommendation from safety monitoring committee
|
AG10 Pharmacodynamic Assessments of TTR stabilization by Fluorescent Polarization Exclusion Assay
Time Frame: up to 60 Months or study completion by recommendation from safety monitoring committee
|
AG10 binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: Fluorescent Polarization Exclusion Assay (FPE)
|
up to 60 Months or study completion by recommendation from safety monitoring committee
|
AG10 Pharmacodynamic Assessments of TTR stabilization by Western Blot
Time Frame: up to 60 Months or study completion by recommendation from safety monitoring committee
|
AG10 binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: Immunoblotting (Western Blot)
|
up to 60 Months or study completion by recommendation from safety monitoring committee
|
AG10 Pharmacodynamic Assessments: prealbumin
Time Frame: up to 60 Months or study completion by recommendation from safety monitoring committee
|
AG10 binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: quantitation of prealbumin (TTR).
|
up to 60 Months or study completion by recommendation from safety monitoring committee
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG10-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyloid Cardiomyopathy
-
PfizerActive, not recruitingTransthyretin Amyloid CardiomyopathyKorea, Republic of
-
PfizerCompletedTransthyretin Amyloid CardiomyopathyChina
-
Algalarrondo VincentBichat Hospital; BioquantisRecruitingTransthyretin Cardiac Amyloidosis | Transthyretin Amyloid Cardiomyopathy | Amyloid CardiomyopathyFrance
-
University of TriestePfizerUnknownAmyloid CardiomyopathyItaly
-
Medical University of GrazMedical University InnsbruckRecruitingAmyloid Cardiomyopathy | Wild Type ATTR AmyloidosisAustria
-
AstraZenecaRecruiting
-
PfizerNot yet recruitingTransthyretin Amyloid Cardiomyopathy
-
Columbia UniversityCompletedTransthyretin Amyloid CardiomyopathyUnited States
-
PfizerRecruiting
-
PfizerRecruitingATTR-CM (Transthyretin Amyloid Cardiomyopathy)Korea, Republic of
Clinical Trials on AG10
-
Eidos Therapeutics, a BridgeBio companyActive, not recruitingAmyloid Cardiomyopathy, Transthyretin-RelatedUnited States, Spain, Australia, Canada, Italy, Netherlands, Ireland, New Zealand, Belgium, Israel, Greece, Korea, Republic of, Czechia, Brazil, Denmark, Portugal, United Kingdom
-
Eidos Therapeutics, a BridgeBio companyWithdrawnTransthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
-
Eidos Therapeutics, a BridgeBio companyWithdrawnTransthyretin-Related (ATTR) Familial Amyloid PolyneuropathyUnited States
-
Eidos Therapeutics, a BridgeBio companyCompletedFamilial ATTR-CM (ATTRm-CM, or FAC) | Wild-type ATTR-CM (ATTRwt-CM)United States
-
Eidos Therapeutics, a BridgeBio companyCompleted
-
Alexion Pharmaceuticals, Inc.Eidos Therapeutics, a BridgeBio companyActive, not recruitingSymptomatic Transthyretin Amyloid CardiomyopathyJapan
-
Alexion PharmaceuticalsCelerionCompleted
-
Eidos Therapeutics, a BridgeBio companyCelerionCompletedAmyloid Cardiomyopathy, Transthyretin-RelatedUnited States
-
Eidos Therapeutics, a BridgeBio companyCompletedHeart Diseases | Amyloidosis | Cardiomyopathies | Transthyretin Amyloidosis | Amyloid CardiomyopathyUnited States, Netherlands, Ireland, Canada, Italy, Spain, Belgium, New Zealand, Israel, Australia, Portugal, Brazil, Poland, Czechia, Denmark, Greece, Korea, Republic of, United Kingdom